awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41807279-BD3C86A7-F904-4EFD-9C18-A200B733E1F1
Q41807279-BD3C86A7-F904-4EFD-9C18-A200B733E1F1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41807279-BD3C86A7-F904-4EFD-9C18-A200B733E1F1
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
P2860
Q41807279-BD3C86A7-F904-4EFD-9C18-A200B733E1F1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41807279-BD3C86A7-F904-4EFD-9C18-A200B733E1F1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dd891f69f57094da8d290210d49f12fc67164e3e
P2860
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.